GlassScriptPhysician profile
Kelsey Jo Smith
NPI 1679660427
$7,207.31
in general payments reported to CMS, 2019-2025
46 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $686 · 2021: $1,497 · 2022: $1,363 · 2023: $1,089 · 2024: $1,021 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,621.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.00 | 2019-2024 | Ubrelvy, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $777.21 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $571.07 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $490.51 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $455.14 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Medtronic, INC. | $337.07 | 2022-2025 | Inceptiv, Intellis Adaptivestim |
| Pfizer INC. | $298.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $271.20 | 2019-2024 | Xarelto |
| Supernus Pharmaceuticals, INC. | $259.81 | 2021-2024 | Qelbree |
| Novo Nordisk INC | $247.20 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.75 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.71 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $194.11 | 2020-2022 | |
| Amarin Pharma, INC. | $176.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $160.83 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.